Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,331 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Spinal Cord Injuries
Interventions
No intervention
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Depression, Asthma
Interventions
High severity group: Escitalopram, High severity group: Placebo, Low severity group: Escitalopram, Low severity group: Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 2 Interventional Results available

Vortioxetine for Binge Eating Disorder

NCT02528409
Conditions
Binge Eating Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Loneliness, Mood, Quality of Life
Interventions
Proactive social robot
Device
Lead sponsor
Baycrest
Other
Eligibility
70 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Intern Health Study 2025

NCT07052357
Conditions
Depression - Major Depressive Disorder, Mood, Sleep, Physical Activity
Interventions
Intern Health Study behavioral change mobile notification
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Diabetes Mellitus, Type 2
Interventions
Peers LEAD plus HLWD
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
20 Years to 90 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Completed Not applicable Interventional Results available

Depression, Obesity and Inflammatory Markers

NCT02765100
Conditions
Bipolar Disorder, Depression, Obesity
Interventions
Minocycline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Completed No phase listed Observational Accepts healthy volunteers

Exploring Biomarkers for Depression

NCT01424111
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Healthy Control
Drug · Other
Lead sponsor
Wyss Institute at Harvard University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
Interventions
Brentuximab Vedotin, Crizotinib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Methotrexate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
154
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Completed Phase 2 Interventional Results available

Ketamine and Nitroprusside for Depression

NCT03102736
Conditions
Depression
Interventions
Placebos, Ketamine, Nitroprusside
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Atlanta, Georgia
Conditions
Treatment Resistant Depression
Interventions
Sham-stimulation, Active-stimulation
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
22 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Conditions
Major Depressive Disorder
Interventions
ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Tucson, Arizona • Oceanside, California • Santa Ana, California + 24 more
Conditions
Major Depression, Cancer, Diabetes, Cardiovascular Diseases
Interventions
Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement)
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Completed Phase 2 Interventional Results available

Ketamine for Depression and Suicide Risk

NCT02094898
Conditions
Depression, Suicide
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Depression
Interventions
Scopolamine and naltrexone, placebo arm
Drug
Lead sponsor
The Taub Group
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Completed Phase 1Phase 2 Interventional

Cognitive Training for Depression

NCT01936506
Conditions
Major Depressive Disorder
Interventions
Cognitive Training A, Cognitive Training B
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder, Anxiety
Interventions
transcranial direct current stimulation using a Soterix mini-CT device
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 28 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Major Depressive Disorder
Interventions
Lithium, Ketamine
Drug
Lead sponsor
James Murrough
Other
Eligibility
21 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Terminated No phase listed Observational Results available

Pharmacogenomics for Antidepressant Guidance and Education

NCT01555021
Conditions
Treatment Resistant Depression
Interventions
Genotyping assays
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Major Depressive Disorder
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
8,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Major Depressive Disorder
Interventions
Active - HD tDCS, Sham - HD tDCS
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Results available

Evaluation of Web-Based CBT for Women Veterans With PTSD

NCT02917447
Conditions
PTSD
Interventions
DESTRESS-WV, Phone Monitoring
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
Sparrow Therapy System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas